Polylactide-based Magnetic Spheres as Efficient Carriers for Anticancer Drug Delivery
Source abstract
Abstract
To improve traditional cancer therapies, we synthesized polylactide (PLA) spheres coencapsulating magnetic nanoparticles (MNPs, Fe3O4) and an anticancer drug (doxorubicin, DOX). The synthesis process involves the preparation of Fe3O4 NPs by a coprecipitation method and then PLA/DOX/Fe3O4 spheres using the solvent evaporation (oil-in-water) technique. The Fe3O4 NPs were coated with oleic acid to improve their hydrophobicity and biocompatibility for medical applications. The structure, morphology and properties of the MNPs and PLA/DOX/Fe3O4 spheres were studied using various techniques, such as FTIR, SEM, TEM, TGA, VSM, UV-vis spectroscopy, and zeta potential measurements. The in vitro DOX release from the spheres was prolonged, sustained, and pH-dependent and fit a zero-order kinetics model and an anomalous mechanism. Interestingly, the spheres did not show a DOX burst effect, ensuring the minimal exposure of the healthy cells and an increased drug payload at the tumor site. The pronounced biocompatibility of the PLA/DOX/Fe3O4 spheres with HeLa cells was proven by a WST assay. In summary, the synthesized PLA/DOX/Fe3O4 spheres have the potential for magnetic targeting of tumor cells to transform conventional methods.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Graphene and Nanomaterials Applications · Advanced Drug Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
DST/CSIR National Centre for Nanostructured Materials, Council for Scientific and Industrial Research, Pretoria 0001, South Africa
Department of Applied Chemistry, University of Johannesburg, Doornfontein, Johannesburg 2028, South Africa
Materials Science and Manufacturing, Council for Scientific and Industrial Research, Pretoria 0001, South Africa
Funding
National Research Foundation · Council for Scientific and Industrial Research · Department of Science and Technology, Ministry of Science and Technology · University of Johannesburg
References (51)
Show source-provided references
1. 10.1016/j.nano.2011.05.01610.1016/j.nano.2011.05.016 ↗
2. 10.1016/j.apsb.2013.02.00610.1016/j.apsb.2013.02.006 ↗
3. 10.2478/v10019-011-0001-z10.2478/v10019-011-0001-z ↗
4. 10.1016/j.addr.2011.06.00310.1016/j.addr.2011.06.003 ↗
5. Orive G. · Cancer Therapy · 2005 · 3 · 131
6. 10.1021/cm702278u10.1021/cm702278u ↗
7. 10.1021/mp700128510.1021/mp7001285 ↗
8. 10.1016/S0168-3659(01)00342-X10.1016/S0168-3659(01)00342-X ↗
9. 10.1016/j.biomaterials.2008.07.00410.1016/j.biomaterials.2008.07.004 ↗
10. 10.1021/la062527g10.1021/la062527g ↗
11. 10.2147/NSA.S2432810.2147/NSA.S24328 ↗
12. 10.1016/j.addr.2008.03.01810.1016/j.addr.2008.03.018 ↗
13. 10.1016/j.biomaterials.2011.09.08710.1016/j.biomaterials.2011.09.087 ↗
14. 10.1002/adma.20080236610.1002/adma.200802366 ↗
15. 10.3390/ijms14081591010.3390/ijms140815910 ↗
16. 10.2147/IJN.S4377010.2147/IJN.S43770 ↗
17. 10.1016/j.rpor.2013.09.01110.1016/j.rpor.2013.09.011 ↗
18. 10.1002/elan.20060378510.1002/elan.200603785 ↗
19. Kutushov, M. V.; Kuznetsov, A. A.; Filippov, V. I.; Kuznetsov, O. A.Scientific and Clinical Applications of Magnetic Carriers;Plenum Press:New York, 1997; pp391–397.10.1007/978-1-4757-6482-6_30 ↗
20. 10.1016/j.progpolymsci.2010.08.00510.1016/j.progpolymsci.2010.08.005 ↗
21. 10.1016/j.addr.2009.11.00210.1016/j.addr.2009.11.002 ↗
22. 10.1016/j.phrs.2010.01.01410.1016/j.phrs.2010.01.014 ↗
23. 10.1016/j.jmmm.2011.05.04510.1016/j.jmmm.2011.05.045 ↗
24. 10.2147/IJN.S2862910.2147/IJN.S28629 ↗
25. 10.1016/j.ijpharm.2006.06.02910.1016/j.ijpharm.2006.06.029 ↗
26. 10.2165/00003495-199700544-0000310.2165/00003495-199700544-00003 ↗
27. Goodman M. F. · J. Biol. Chem. · 1977 · 252 · 267010.1016/S0021-9258(17)40510-2 ↗
28. 10.2147/IJN.S1853510.2147/IJN.S18535 ↗
29. 10.1016/j.ejpb.2014.09.01210.1016/j.ejpb.2014.09.012 ↗
30. 10.1016/j.biomaterials.2013.07.07510.1016/j.biomaterials.2013.07.075 ↗
31. 10.1016/j.nano.2015.03.01510.1016/j.nano.2015.03.015 ↗
32. 10.1016/j.ejpb.2015.07.00510.1016/j.ejpb.2015.07.005 ↗
33. 10.1016/S0927-7757(02)00305-910.1016/S0927-7757(02)00305-9 ↗
34. 10.1016/j.colsurfa.2013.04.02110.1016/j.colsurfa.2013.04.021 ↗
35. 10.1021/la104471r10.1021/la104471r ↗
36. 10.1016/j.jcis.2007.01.08110.1016/j.jcis.2007.01.081 ↗
37. 10.5012/bkcs.2006.27.2.23710.5012/bkcs.2006.27.2.237 ↗
38. 10.1016/j.biomaterials.2004.10.01210.1016/j.biomaterials.2004.10.012 ↗
39. 10.3390/molecules1807753310.3390/molecules18077533 ↗
40. 10.1088/1742-6596/187/1/01204810.1088/1742-6596/187/1/012048 ↗
41. 10.1590/S0366-6913200900040001310.1590/S0366-69132009000400013 ↗
42. 10.1016/j.msec.2010.01.00610.1016/j.msec.2010.01.006 ↗
43. 10.1007/s10544-007-9139-210.1007/s10544-007-9139-2 ↗
44. Xu R. · 2001
45. Lübbe A. S. · Cancer Res. · 1996 · 56 · 4694
46. 10.1016/S0928-0987(01)00095-110.1016/S0928-0987(01)00095-1 ↗
47. 10.1186/1556-276X-6-26010.1186/1556-276X-6-260 ↗
48. 10.1016/j.talanta.2013.01.03710.1016/j.talanta.2013.01.037 ↗
49. 10.1016/j.toxrep.2014.11.00210.1016/j.toxrep.2014.11.002 ↗
50. 10.2478/v10019-011-0001-z10.2478/v10019-011-0001-z ↗
51. 10.3402/nano.v1i0.535810.3402/nano.v1i0.5358 ↗